EC Number | Activating Compound | Comment | Organism | Structure |
---|---|---|---|---|
3.4.11.2 | additional information | CD13 expression is regulated by differentiation agents, such as phorbol esters, transforming growth factor-beta, interleukin-4 and interleukin-10 | Homo sapiens |
EC Number | Cloned (Comment) | Organism |
---|---|---|
3.4.11.2 | expressed in Escherichia coli | Homo sapiens |
EC Number | Crystallization (Comment) | Organism |
---|---|---|
3.4.11.2 | - |
Homo sapiens |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.11.2 | 2',3-dinitroflavone-8-acetic acid | - |
Homo sapiens | |
3.4.11.2 | actinonin | - |
Homo sapiens | |
3.4.11.2 | adhesion/signaling-inducing antibody 452 | - |
Homo sapiens | |
3.4.11.2 | amastatin | - |
Homo sapiens | |
3.4.11.2 | anti-CD13 monoclonl antibody WM15 | - |
Homo sapiens | |
3.4.11.2 | bestatin | ubenimex | Homo sapiens | |
3.4.11.2 | betulinic acid | - |
Homo sapiens | |
3.4.11.2 | bradykinin | bradykinin is resistant to hydrolysis by CD13, acting rather as a natural inhibitor | Homo sapiens | |
3.4.11.2 | coronavirus infection inhibitor Y2-K | - |
Homo sapiens | |
3.4.11.2 | curcumin | - |
Homo sapiens | |
3.4.11.2 | ezetimibe | - |
Homo sapiens | |
3.4.11.2 | icatibant | - |
Homo sapiens | |
3.4.11.2 | leuhistin | - |
Homo sapiens | |
3.4.11.2 | LVV-hemorphin-7 | - |
Homo sapiens | |
3.4.11.2 | additional information | the neuropeptide substance P inhibits enkephalin cleavage by CD13 | Homo sapiens | |
3.4.11.2 | phebestin | - |
Homo sapiens | |
3.4.11.2 | probestin | - |
Homo sapiens | |
3.4.11.2 | puromycin | - |
Homo sapiens |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
3.4.11.2 | membrane | - |
Homo sapiens | 16020 | - |
EC Number | Metals/Ions | Comment | Organism | Structure |
---|---|---|---|---|
3.4.11.2 | Zn2+ | dependent on | Homo sapiens |
EC Number | Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|---|
3.4.11.2 | 160000 | - |
about 160000 Da | Homo sapiens |
3.4.11.2 | 260000 | - |
the protein present in sera of patients with cholestatic diseases is later found to be a high molecular isoform of CD13 (260 kDa) | Homo sapiens |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.11.2 | additional information | Homo sapiens | where initial removal of the NH2-terminal dipeptide from CXCL11 by CD26 allows for further truncation by CD13 | ? | - |
? | |
3.4.11.2 | additional information | Homo sapiens | aminopeptidase N removes N-terminal amino acids from unsubstituted oligopeptides, amide or arylamide, with the exception of peptides with Pro in the penultimate position, the order of favored substrates is Ala>Phe>Tyr>Leu>Arg>Thr>Trp>Lys> Ser>Asp>His>Val | ? | - |
? | |
3.4.11.2 | additional information | Homo sapiens | CD13 degrades the chemokine CXCL11, downregulates CXCR4 and modulates stromal cell-derived factor-1 (also known as CXCL12)-induced migration | ? | - |
? | |
3.4.11.2 | additional information | Homo sapiens | CD13 hydrolyzes synthetic oligopeptides corresponding to the N terminus of interleukin-1a, interleukin-1b and interleukin-2, although natural interleukin-2 and G-CSF are resistant to hydrolysis | ? | - |
? | |
3.4.11.2 | additional information | Homo sapiens | CD13 is a receptor for human coronavirus 229E and human cytomegalovirus | ? | - |
? | |
3.4.11.2 | additional information | Homo sapiens | in vitro, CD13 participates in the metabolism of glutathione, somatostatin, thymopentin, neurokinin A, splenopentin, nociceptin (orphanin) FQ, and peptides derived from the thrombin receptor | ? | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.11.2 | Homo sapiens | - |
- |
- |
EC Number | Posttranslational Modification | Comment | Organism |
---|---|---|---|
3.4.11.2 | glycoprotein | - |
Homo sapiens |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.4.11.2 | acute myeloid leukemia cell | - |
Homo sapiens | - |
3.4.11.2 | alveolar macrophage | - |
Homo sapiens | - |
3.4.11.2 | bile | - |
Homo sapiens | - |
3.4.11.2 | CL1-0 cell | - |
Homo sapiens | - |
3.4.11.2 | dendritic cell | - |
Homo sapiens | - |
3.4.11.2 | endothelial cell | - |
Homo sapiens | - |
3.4.11.2 | intestinal epithelium | - |
Homo sapiens | - |
3.4.11.2 | liver | - |
Homo sapiens | - |
3.4.11.2 | lymphocyte | - |
Homo sapiens | - |
3.4.11.2 | monocyte | - |
Homo sapiens | - |
3.4.11.2 | nervous system | - |
Homo sapiens | - |
3.4.11.2 | pericyte | - |
Homo sapiens | - |
3.4.11.2 | renal epithelium | - |
Homo sapiens | - |
3.4.11.2 | serum | - |
Homo sapiens | - |
3.4.11.2 | spermatid | - |
Homo sapiens | - |
3.4.11.2 | synoviocyte | - |
Homo sapiens | - |
3.4.11.2 | U-937 cell | - |
Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.11.2 | angiotensin III + H2O | - |
Homo sapiens | angiotensin IV + L-Arg | - |
? | |
3.4.11.2 | entactin + H2O | - |
Homo sapiens | ? | - |
? | |
3.4.11.2 | L-Ala-p-nitroanilide + H2O | - |
Homo sapiens | L-Ala + p-nitroaniline | - |
? | |
3.4.11.2 | Leu-enkephalin-L-Tyr-Gly + H2O | - |
Homo sapiens | Leu + enkephalin-L-Tyr-Gly | - |
? | |
3.4.11.2 | Lys-des-Arg9-bradykinin + H2O | - |
Homo sapiens | ? | - |
? | |
3.4.11.2 | lysyl-bradykinin + H2O | - |
Homo sapiens | ? | - |
? | |
3.4.11.2 | Met-enkephalin-L-Tyr-Gly + H2O | - |
Homo sapiens | Met + enkephalin L-Tyr-Gly | - |
? | |
3.4.11.2 | additional information | where initial removal of the NH2-terminal dipeptide from CXCL11 by CD26 allows for further truncation by CD13 | Homo sapiens | ? | - |
? | |
3.4.11.2 | additional information | aminopeptidase N removes N-terminal amino acids from unsubstituted oligopeptides, amide or arylamide, with the exception of peptides with Pro in the penultimate position, the order of favored substrates is Ala>Phe>Tyr>Leu>Arg>Thr>Trp>Lys> Ser>Asp>His>Val | Homo sapiens | ? | - |
? | |
3.4.11.2 | additional information | CD13 degrades the chemokine CXCL11, downregulates CXCR4 and modulates stromal cell-derived factor-1 (also known as CXCL12)-induced migration | Homo sapiens | ? | - |
? | |
3.4.11.2 | additional information | CD13 hydrolyzes synthetic oligopeptides corresponding to the N terminus of interleukin-1a, interleukin-1b and interleukin-2, although natural interleukin-2 and G-CSF are resistant to hydrolysis | Homo sapiens | ? | - |
? | |
3.4.11.2 | additional information | CD13 is a receptor for human coronavirus 229E and human cytomegalovirus | Homo sapiens | ? | - |
? | |
3.4.11.2 | additional information | in vitro, CD13 participates in the metabolism of glutathione, somatostatin, thymopentin, neurokinin A, splenopentin, nociceptin (orphanin) FQ, and peptides derived from the thrombin receptor | Homo sapiens | ? | - |
? | |
3.4.11.2 | tuftsin + H2O | the first peptidic bond of this tuftsin is hydrolyzed by CD13, generating an antagonist that competes for receptor binding and thus regulating tuftsin functions | Homo sapiens | ? | - |
? | |
3.4.11.2 | Type IV collagen + H2O | - |
Homo sapiens | ? | - |
? |
EC Number | Subunits | Comment | Organism |
---|---|---|---|
3.4.11.2 | dimer | x-ray crystallography | Homo sapiens |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.4.11.2 | aminopeptidase N | the enzyme is named aminopeptidase N because of its preference for neutral amino acids | Homo sapiens |
3.4.11.2 | APN | - |
Homo sapiens |
3.4.11.2 | CD13 | - |
Homo sapiens |